


Raltegravir



CAS

518048-05-0

Status

Development

Inquiry

Raltegravir is a virostatic used in the treatment of viruses (including HIV viruses). It acts as the first approved agent as an integrase inhibitor. Integrase funnels the viral DNA into the host's DNA strand. Raltegravir should be better tolerated and show success especially in multi-resistant viruses. It was permitted in the US and EU in 2007.

Description

Formula	C ₂₀ H ₂₁ FN ₆ O ₅
Molecular weight	444.42 g/mol
Molecular size	small
Controlled Substance	no
Precursor	no
Indications	Antivirals for systemic use

Your Contact



Marius Hang

International Division

Director API Export

Midas Pharma GmbH

Rheinstr. 49

55218 Ingelheim

Germany

[Send E-Mail](#)

Disclaimer

The information contained herein is the proprietary information of Midas Pharma GmbH and its affiliates. This information is provided to you solely for your evaluation, to determine your interest in a potential business relationship with Midas Pharma GmbH and/or its affiliates. Midas Pharma GmbH excludes any express or implied representations, guarantees or warranties of whatsoever nature, including but not limited to the warranties for the completeness or accuracy of the information provided herein.

No information provided herein – including any reference to any product or service – constitutes an offer for sale, or shall be construed as representing an offer for sale. In particular, nothing herein should be construed as a promotion or advertisement for any product, or for the use of any product, that infringes valid patents and/or is not authorized by the laws and regulations of your country of residence.